Compare NEXT & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEXT | HROW |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | 237 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2014 | N/A |
| Metric | NEXT | HROW |
|---|---|---|
| Price | $5.60 | $36.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $7.50 | ★ $71.14 |
| AVG Volume (30 Days) | ★ 2.8M | 767.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $44.68 |
| Revenue Next Year | N/A | $40.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.75 | $20.85 |
| 52 Week High | $12.12 | $54.98 |
| Indicator | NEXT | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 28.17 |
| Support Level | $5.58 | $36.23 |
| Resistance Level | $6.32 | $40.64 |
| Average True Range (ATR) | 0.38 | 2.95 |
| MACD | 0.03 | -1.89 |
| Stochastic Oscillator | 42.00 | 8.30 |
NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas, the sale of LNG, and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions, advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.